Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma Clinical Trial

Official title:
A Study to Evaluate the Effects of Radiotherapy Combined With Tyrosine Kinase Inhibitor (TKI) and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(PVTT)

Status Recruiting

Clinical Trial Summary

The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Hepatocellular
Stage IIIA Hepatocellular Carcinoma

Clinical Trial Details

NCT number	NCT06061445
Study type	Interventional
Source	Fujian Cancer Hospital
Contact	Shaohua Xu, Master
Phone	13599253863
Email	xshzss@126.com
Status	Recruiting
Phase	N/A
Start date	January 9, 2024
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02072486` - Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	N/A
Completed	`NCT02837029` - Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer	Phase 1
Completed	`NCT02507765` - Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Phase 1
Active, not recruiting	`NCT03211416` - Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer	Phase 1/Phase 2